Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-007 plus toripalimab in advanced malignancies
CTR20212700Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of alcestobart, toripalimab in cancer, sponsored by Leads Biolabs. Started Nov 2021; status: completed.
02
Drugs
alcestobarttoripalimab
03
Conditions
cancer
Beyond the preview
Go deeper on CTR20212700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212700.